AFP and hepatocellular carcinoma: A previous cross-country cohort study comprising 2,400 individuals found that the combined “GALAD” score, encompassing gender, age, AFP, AFP-L3, and PIVKA-II, exhibited relatively high sensitivity for both random and early-stage HCC screening, achieving over 70% and 60% sensitivity, respectively.14